Shukra Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis

SHUKRAPHAR Pharmaceuticals
Screen Shukra Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹51.45
▼ -2.70 (-4.99%)
2026-01-06 00:00:00
Market Cap ₹2,594.42 Cr.
P/B Ratio 41.50
EPS (TTM) ₹0.22
Dividend Yield 0.02%
Debt to Equity 0.06
52W High ₹64.43
52W Low ₹12.09
Operating Margin 27.00%
Profit Margin 30.00%
Revenue (TTM) ₹40.00
EBITDA ₹17.00
Net Income ₹12.00
Total Assets ₹87.00
Total Equity ₹63.00

Shukra Pharmaceuticals Share Price History - Stock Screener Chart

Screen SHUKRAPHAR historical share price movements with interactive charts. Analyze price trends and patterns.

Shukra Pharmaceuticals Company Profile - Fundamental Screener

Screen Shukra Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SHUKRAPHAR shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE551C01044

Shukra Pharmaceuticals Balance Sheet Screener - Fundamental Analysis

Fair Value Analysis
Screen SHUKRAPHAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Assets
Total Assets 87 78 75 35 36 34 28 24 19 17
Current Assets 65 56 53 16 16 15 11 8 7 6
Fixed Assets 19 20 20 18 18 17 16 14 10 10
Liabilities
Total Liabilities 87 78 75 35 36 34 28 24 19 17
Current Liabilities 7 6 7 6 13 11 9 6 3 3
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 63 58 25 16 16 15 15 15 15 14
Share Capital 44 11 4 2 2 2 2 2 2 2
Reserves & Surplus 19 47 21 15 14 14 14 13 13 13
Screen SHUKRAPHAR income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
Item None-None 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March
Revenue 40 37 77 60 21 12 12 6 6 5 5 4
Expenses 23 20 55 54 18 10 10 4 4 4 4 3
EBITDA 17 17 22 7 3 2 2 2 2 2 1 1
Operating Profit % 27.00% 39.00% 26.00% 9.00% 14.00% 13.00% 13.00% 29.00% 30.00% 29.00% 24.00% -10.00%
Depreciation 3 3 2 2 2 2 2 1 1 1 0 1
Interest 1 1 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 13 13 20 4 1 0 0 1 1 1 0 0
Tax 4 4 1 0 0 0 0 0 0 1 0 0
Net Profit 12 10 19 4 1 0 0 1 1 1 0 0
EPS 0.90 0.22 16.93 26.21 4.79 1.20 0.23 2.95 3.36 3.21 0.76 0.84

Shukra Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen SHUKRAPHAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 8 -5 3 8 1 1 0 1 0 3
Investing Activities -1 -1 -4 -2 -2 -3 -3 -5 -1 0
Financing Activities -5 12 5 -7 2 2 2 4 0 -1
Net Cash Flow 2 6 4 0 0 0 0 -1 -1 1
Screen SHUKRAPHAR shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar
Promoter Holding 50.96% 50.96% 50.96% 50.96% 50.96% 50.96% 50.96% 50.90%
FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 9.29% 28.69% 9.20% 9.79% 9.19% 9.25% 9.41% 29.14%
Other Holding 39.64% 20.24% 39.72% 39.14% 39.73% 39.68% 39.51% 19.85%
Shareholder Count 18,231 20,337 21,441 12,974 14,989 16,321 17,844 9,544

Shukra Pharmaceuticals Dividend Screener - Share Yield Analysis

Screen SHUKRAPHAR dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Period Dividend Per Share Dividend Yield
2025-March ₹0.01 0.02%
2024-March ₹1.00 4.58%
2023-March ₹0.50 6.13%
2022-March ₹0.50 42.74%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.50 208.33%
2018-March ₹0.50 263.16%
2017-March ₹0.50 156.25%
2016-March ₹0.00 0.00%

Shukra Pharmaceuticals Index Membership - Market Screener Classification

Screen SHUKRAPHAR by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Shukra Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Shukra Pharmaceuticals Market Events Screener - Corporate Actions

Screen SHUKRAPHAR market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 0.01 /share 126.55%
Dividend ₹ 0.50 /share 253.33%
Dividend ₹ 1.00 /share -40.51%
Annual General Meeting NA 5.63%
Dividend ₹ 0.50 /share 76.74%
Annual General Meeting NA 34.10%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -0.17%
2025-11-01 2025-11-01 Extraordinary General Meeting NA 19.04%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -9.76%
2025-05-29 2025-05-29 Quarterly Result Announcement NA -5.08%
2025-03-21 2025-01-29 Split 1:10 0.00%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -9.64%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -6.35%
2024-08-23 2024-08-23 Extraordinary General Meeting NA -31.85%
2024-04-19 2024-04-20 Bonus 3:1 12.62%

Shukra Pharmaceuticals Competitors Screener - Peer Comparison

Screen SHUKRAPHAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 412,950 39.35 54,729 9.71% 10,980 39.06
Divis Laboratories 170,710 68.64 9,712 18.67% 2,191 44.96
Torrent Pharmaceuticals 128,789 60.42 11,539 6.99% 1,911 59.35
Cipla 120,673 22.17 28,410 7.12% 5,291 42.76
Dr Reddys Laboratories 105,289 18.42 33,741 16.73% 5,725 49.97
Lupin 95,151 21.87 22,910 13.74% 3,306 50.10
Zydus Life Science 91,366 18.03 23,511 18.55% 4,615 34.06
Mankind Pharma 89,434 50.11 12,744 20.90% 2,007 40.67
Aurobindo Pharma 68,703 20.16 32,346 9.43% 3,484 46.33
Alkem Laboratories 65,211 26.89 13,458 3.70% 2,216 37.45

Shukra Pharmaceuticals Company Announcements - News Screener

Screen SHUKRAPHAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-01-06 Reconstitution Of Committees Of The Company. View
2026-01-06 Announcement under Regulation 30 (LODR)-Change in Management View
2026-01-06 Announcement under Regulation 30 (LODR)-Resignation of Director View
2026-01-06 Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Held On December 30 2025. View
2025-12-30 Closure of Trading Window View
2025-12-29 Intimation For Corporate Announcement Under Regulation 30 Of SEBI (LODR) Regulations Working In The Government Market Of Gujarat For Our Laparoscopic Sets And Accessories. View
2025-12-05 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-12-03 Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order View
2025-12-03 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot View
2025-11-29 Approval Of Continuation Of Directorship Of Mr. Jitendra Somchand Shah Non-Executive Independent Director Who Has Attained Age Of 75 Years On September 22 2025 Subject To Approval Of Shareholders. View
2025-11-29 Outcome Of The Meeting Of The Board Of Directors Held On Saturday November 29 2025 View
2025-11-29 Board Meeting Outcome for Outcome Of The Meetins Of The Board Of Directors Held On Saturdav. November 29.2025. View
2025-11-14 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-11-13 Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30 2025 Along With The Auditors Limited Review Reports In Accordance With The Provisions Of Regulation 33 Of The SEBI Listing Regulations. View
2025-11-13 Board Meeting Outcome for Outcome Of Board Meeting Held On November 13 2025. View
2025-11-10 Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Incorporation Of Subsidiary Company. View
2025-11-01 Voting Result Along With Scrutinizer Report Of Extra Ordinary General Meeting (EOGM) Of The Company Held On November 01 2025. View
2025-11-01 Shareholder Meeting / Postal Ballot-Outcome of EGM View
2025-10-31 Board Meeting Intimation for Unaudited Financial Result For The Half Year Ended On 30TH September 2025 Along With The Auditors Limited Review Report. View
2025-10-31 Receipt Of Distributorship Rights View